Cargando…

Clinical and Neuroimaging Characteristics of Pediatric Acute Disseminating Encephalomyelitis With and Without Antibodies to Myelin Oligodendrocyte Glycoprotein

Objective: To compare the clinical and neuroimaging characteristics of anti-myelin oligodendrocyte glycoprotein antibody (MOG-ab) negative and positive pediatric acute disseminating encephalomyelitis (ADEM) patients. Methods: Clinical characteristics, neuroimaging features, ancillary examination res...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Min, Shen, Jin, Zhou, Shuizhen, Du, Xiaonan, Li, Wenhui, Yu, Lifei, Zhang, Yunjian, Wang, Yi, Zhang, Linmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717994/
https://www.ncbi.nlm.nih.gov/pubmed/33329345
http://dx.doi.org/10.3389/fneur.2020.593287
_version_ 1783619418126811136
author Zhang, Min
Shen, Jin
Zhou, Shuizhen
Du, Xiaonan
Li, Wenhui
Yu, Lifei
Zhang, Yunjian
Wang, Yi
Zhang, Linmei
author_facet Zhang, Min
Shen, Jin
Zhou, Shuizhen
Du, Xiaonan
Li, Wenhui
Yu, Lifei
Zhang, Yunjian
Wang, Yi
Zhang, Linmei
author_sort Zhang, Min
collection PubMed
description Objective: To compare the clinical and neuroimaging characteristics of anti-myelin oligodendrocyte glycoprotein antibody (MOG-ab) negative and positive pediatric acute disseminating encephalomyelitis (ADEM) patients. Methods: Clinical characteristics, neuroimaging features, ancillary examination results, and outcomes of pediatric ADEM patients were retrospectively reviewed between February 2016 and July 2019. Results: Among 37 pediatric ADEM patients, 24 patients (11 girls and 13 boys) fulfilled the inclusion criteria. The median age was 72 (range 19–156) months, and the median follow-up duration was 20 (range 12–48) months. Children with ADEM and MOG-abs presented with increased ataxia, reduced bladder/rectum dysfunction, and paralysis compared to children without MOG-abs. An important finding was that no significant differences existed in age at symptom onset, sex ratio, time from immunotherapy to clinical improvement and clinical recovery, or modified Rankin Scale (mRS) at the last follow-up. More typical cerebral MRI lesions were detected in patients with ADEM and MOG-abs than in children without MOG-abs [11/12 (91.7%) vs. 8/12 (66.7%)]. Cerebellar lesions were higher in ADEM patients with MOG-abs (7/12, 58.3%) than in those without MOG-abs (2/12, 16.7%). While seven children had abnormal spinal MRI findings (7/12, 58.3%) and five had longitudinally extensive transverse myelitis (LETM) (5/12, 41.7%) per group, the coexistence of spinal dysfunction and abnormal spinal MRI was lower in ADEM with MOG-abs (2/12, 16.7%) than in children without MOG-abs (7/12, 58.3%). Clinical improvement was achieved 1 week after immunotherapy. Most children in both groups achieved clinical recovery within 3 months after immunotherapy, although two (16.7%) patients with ADEM and MOG-abs had persistent neurological sequelae at the last follow-up. Conclusion: MOG-abs-positive ADEM is a major subtype of pediatric ADEM. Ataxia is the most common clinical presentation in pediatric ADEM and MOG-abs. Children with ADEM and MOG-abs have similar patterns of lesions characterized by large, bilateral, widespread lesions, as well as more cerebellar lesions than children without MOG-abs. Most spinal lesions were subclinical in pediatric ADEM with MOG-abs. A favorable prognosis can be achieved for pediatric ADEM regardless of the MOG-abs status. However, some patients with MOG-abs are likely to have more severe neurological sequelae.
format Online
Article
Text
id pubmed-7717994
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77179942020-12-15 Clinical and Neuroimaging Characteristics of Pediatric Acute Disseminating Encephalomyelitis With and Without Antibodies to Myelin Oligodendrocyte Glycoprotein Zhang, Min Shen, Jin Zhou, Shuizhen Du, Xiaonan Li, Wenhui Yu, Lifei Zhang, Yunjian Wang, Yi Zhang, Linmei Front Neurol Neurology Objective: To compare the clinical and neuroimaging characteristics of anti-myelin oligodendrocyte glycoprotein antibody (MOG-ab) negative and positive pediatric acute disseminating encephalomyelitis (ADEM) patients. Methods: Clinical characteristics, neuroimaging features, ancillary examination results, and outcomes of pediatric ADEM patients were retrospectively reviewed between February 2016 and July 2019. Results: Among 37 pediatric ADEM patients, 24 patients (11 girls and 13 boys) fulfilled the inclusion criteria. The median age was 72 (range 19–156) months, and the median follow-up duration was 20 (range 12–48) months. Children with ADEM and MOG-abs presented with increased ataxia, reduced bladder/rectum dysfunction, and paralysis compared to children without MOG-abs. An important finding was that no significant differences existed in age at symptom onset, sex ratio, time from immunotherapy to clinical improvement and clinical recovery, or modified Rankin Scale (mRS) at the last follow-up. More typical cerebral MRI lesions were detected in patients with ADEM and MOG-abs than in children without MOG-abs [11/12 (91.7%) vs. 8/12 (66.7%)]. Cerebellar lesions were higher in ADEM patients with MOG-abs (7/12, 58.3%) than in those without MOG-abs (2/12, 16.7%). While seven children had abnormal spinal MRI findings (7/12, 58.3%) and five had longitudinally extensive transverse myelitis (LETM) (5/12, 41.7%) per group, the coexistence of spinal dysfunction and abnormal spinal MRI was lower in ADEM with MOG-abs (2/12, 16.7%) than in children without MOG-abs (7/12, 58.3%). Clinical improvement was achieved 1 week after immunotherapy. Most children in both groups achieved clinical recovery within 3 months after immunotherapy, although two (16.7%) patients with ADEM and MOG-abs had persistent neurological sequelae at the last follow-up. Conclusion: MOG-abs-positive ADEM is a major subtype of pediatric ADEM. Ataxia is the most common clinical presentation in pediatric ADEM and MOG-abs. Children with ADEM and MOG-abs have similar patterns of lesions characterized by large, bilateral, widespread lesions, as well as more cerebellar lesions than children without MOG-abs. Most spinal lesions were subclinical in pediatric ADEM with MOG-abs. A favorable prognosis can be achieved for pediatric ADEM regardless of the MOG-abs status. However, some patients with MOG-abs are likely to have more severe neurological sequelae. Frontiers Media S.A. 2020-11-20 /pmc/articles/PMC7717994/ /pubmed/33329345 http://dx.doi.org/10.3389/fneur.2020.593287 Text en Copyright © 2020 Zhang, Shen, Zhou, Du, Li, Yu, Zhang, Wang and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Zhang, Min
Shen, Jin
Zhou, Shuizhen
Du, Xiaonan
Li, Wenhui
Yu, Lifei
Zhang, Yunjian
Wang, Yi
Zhang, Linmei
Clinical and Neuroimaging Characteristics of Pediatric Acute Disseminating Encephalomyelitis With and Without Antibodies to Myelin Oligodendrocyte Glycoprotein
title Clinical and Neuroimaging Characteristics of Pediatric Acute Disseminating Encephalomyelitis With and Without Antibodies to Myelin Oligodendrocyte Glycoprotein
title_full Clinical and Neuroimaging Characteristics of Pediatric Acute Disseminating Encephalomyelitis With and Without Antibodies to Myelin Oligodendrocyte Glycoprotein
title_fullStr Clinical and Neuroimaging Characteristics of Pediatric Acute Disseminating Encephalomyelitis With and Without Antibodies to Myelin Oligodendrocyte Glycoprotein
title_full_unstemmed Clinical and Neuroimaging Characteristics of Pediatric Acute Disseminating Encephalomyelitis With and Without Antibodies to Myelin Oligodendrocyte Glycoprotein
title_short Clinical and Neuroimaging Characteristics of Pediatric Acute Disseminating Encephalomyelitis With and Without Antibodies to Myelin Oligodendrocyte Glycoprotein
title_sort clinical and neuroimaging characteristics of pediatric acute disseminating encephalomyelitis with and without antibodies to myelin oligodendrocyte glycoprotein
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717994/
https://www.ncbi.nlm.nih.gov/pubmed/33329345
http://dx.doi.org/10.3389/fneur.2020.593287
work_keys_str_mv AT zhangmin clinicalandneuroimagingcharacteristicsofpediatricacutedisseminatingencephalomyelitiswithandwithoutantibodiestomyelinoligodendrocyteglycoprotein
AT shenjin clinicalandneuroimagingcharacteristicsofpediatricacutedisseminatingencephalomyelitiswithandwithoutantibodiestomyelinoligodendrocyteglycoprotein
AT zhoushuizhen clinicalandneuroimagingcharacteristicsofpediatricacutedisseminatingencephalomyelitiswithandwithoutantibodiestomyelinoligodendrocyteglycoprotein
AT duxiaonan clinicalandneuroimagingcharacteristicsofpediatricacutedisseminatingencephalomyelitiswithandwithoutantibodiestomyelinoligodendrocyteglycoprotein
AT liwenhui clinicalandneuroimagingcharacteristicsofpediatricacutedisseminatingencephalomyelitiswithandwithoutantibodiestomyelinoligodendrocyteglycoprotein
AT yulifei clinicalandneuroimagingcharacteristicsofpediatricacutedisseminatingencephalomyelitiswithandwithoutantibodiestomyelinoligodendrocyteglycoprotein
AT zhangyunjian clinicalandneuroimagingcharacteristicsofpediatricacutedisseminatingencephalomyelitiswithandwithoutantibodiestomyelinoligodendrocyteglycoprotein
AT wangyi clinicalandneuroimagingcharacteristicsofpediatricacutedisseminatingencephalomyelitiswithandwithoutantibodiestomyelinoligodendrocyteglycoprotein
AT zhanglinmei clinicalandneuroimagingcharacteristicsofpediatricacutedisseminatingencephalomyelitiswithandwithoutantibodiestomyelinoligodendrocyteglycoprotein